Skip to main content Skip to navigation

Other disease modifying drugs


Alemtuzumab (Campath)

  • Coles A, Deans J, Compston A.
    Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench.
    Clin Neurol Neurosurg 2004;106:270-274.

  • Coles A.
    Efficacy of alemtuzumab in treatment-naïve relapsing-remitting multiple sclerosis: analysis after two years of study CAMMS223.
    Academy of American Neurologists 2007; 59th AAN Annual Meeting April 28-May 5 2007; presentation S12.004.
    AAN Meeting abstracts

  • Rose JW, Foley J, Carlson N.
    Monoclonal antibody treatments for multiple sclerosis.
    Curr Neurol Neurosci Rep 2008;8(5):419-426.
    Abstract

Azathioprine

  • Lus G, Romano F, Scuotto A, et al.
    Azathioprine and interferon beta1a in relapsing remitting multiple sclerosis patients: increasing efficacy in combined treatment.
    Eur Neurol 2004;51:15-20.
    Abstract

  • Palace J, Rothwell P.
    New treatments and azathioprine in multiple sclerosis.
    Lancet 1997;350:261.

  • Yudkin PL, Ellison GW, Ghezzi A, et al.
    Overview of azathioprine treatment in multiple sclerosis.
    Lancet 1991;3338:1051-1055.
    Abstract

Cannabis

  • Zajicek J, Fox P, Sanders H, et al.
    Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.
    Lancet 2003;362(9395):1517-1526.
    Abstract

  • Zajicek J, Sanders H, Wright DE, et al.
    Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.
    J Neurol Neurosurg Psych 2005; 76(12): 1664-1669.
    Abstract

Fingolimod (FTY720)

  • Cohen J, et al.
    Oral fingolimod (FTY720) versus interferon beta-1a in relapsing-remitting multiple sclerosis: results from a phase III study (TRANSFORMS).
    Presentation at the American Academy of Neurology Annual Meeting 2009. [S21.004].

  • Kappos L, Antel J, Comi G, et al.
    Oral fingolimod (FTY720) for relapsing multiple sclerosis.
    NEJM 2006;355(11):1124-1140.
    Abstract

  • Montalban X, et al.
    Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: 4-year results from a phase II extension.
    Poster presentation at the American Academy of Neurology Annual Meeting 2009. [P06.128].

Mitoxantrone

  • Boggild M.
    Rationale and experience with combination therapies.
    J Neurol 2006;253 (Suppl 6): vi45-vi51.

  • Harrison E, Porter B.
    A nurse-led, patient centred mitoxantrone service in neurology.
    Br J Nurs 2004;13(17):1021-1023.
    Abstract

  • Hartung HP, Gonsette R, Konig N.
    Mitoxantrone in progressive multiple sclerosis: a placebo controlled, double blind, randomised, multicentre trial.
    Lancet 2002;360:2018-2025.
    Abstract

  • Ramtahal J, Jacob A, Das K, Boggild M.
    Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.
    J Neurol 2006;253(9):1160-1164.
    Abstract

  • Vollmer T, Panitch H, Bar-Or A, et al.
    Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
    Mult Scler 2008;14(5):663-670.
    Abstract

Natalizumab (Tysabri)

  • Polman CH, O'Connor PW, Havrdova E, et al.
    A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
    New England Journal of Medicine 2006; 354(9): 899-910.
    Abstract

  • Rudick RA, Stuart WH, Calabresi PA, et al.
    Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    New England Journal of Medicine 2006; 354(9): 911-923.
    Abstract